STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients
STAT
OCTOBER 21, 2023
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday. The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option.
Let's personalize your content